150 related articles for article (PubMed ID: 3857972)
1. Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study.
Abeloff MD; Finkelstein DM; Chang AY; Camacho FJ; Creech RH; Ettinger DS
Cancer Treat Rep; 1985 Apr; 69(4):451-2. PubMed ID: 3857972
[No Abstract] [Full Text] [Related]
2. Phase II clinical trial of diaziquone in bronchogenic carcinoma.
Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M
Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800
[No Abstract] [Full Text] [Related]
3. Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
Ettinger DS; Finkelstein DM; Harper GR; Ruckdeschel JC; Chang AY; Camacho FJ; Marsh JC; Silber R; Wolter JM
Cancer Treat Rep; 1985 Sep; 69(9):1033-4. PubMed ID: 3861248
[No Abstract] [Full Text] [Related]
4. Phase II study of diaziquone in patients with advanced carcinoma of the lung.
Frytak S; Eagan RT; Creagan ET; Nichols WC
Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455
[No Abstract] [Full Text] [Related]
5. Phase I-II diaziquone chemotherapy in brain tumors.
Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
[No Abstract] [Full Text] [Related]
6. Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
Chan C; Bartolucci A; Brenner D; Presant C; Davila E; Carpenter J; Greco FA; Clamon G; Moore J
Cancer Treat Rep; 1986 Mar; 70(3):427-8. PubMed ID: 3456834
[No Abstract] [Full Text] [Related]
7. Phase II study of diaziquone in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study.
Zidar BL; Baker LH; Rivkin SE; Balcerzak SP; Stephens RL
Cancer Treat Rep; 1985 Sep; 69(9):1035-6. PubMed ID: 4028037
[No Abstract] [Full Text] [Related]
8. Cancer and leukemia group B phase II non-small cell lung carcinoma trial: aziridinylbenzoquinone (AZQ).
Carey RW; Comis RL; Anbar D; Kennedy BJ; Capizzi RL; Shulman P; Booth BW; Green M; Raich PC
Cancer Treat Rep; 1983 Jan; 67(1):95-6. PubMed ID: 6616498
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.
Tilchen EJ; Fleming T; Mills G; Oishi N; Bonnett JD; Natale RB; Harker G; Coltman CA
Cancer Treat Rep; 1987 Dec; 71(12):1309-10. PubMed ID: 3690548
[No Abstract] [Full Text] [Related]
10. Aclarubicin given as continuous infusion in non-small cell bronchogenic carcinoma.
Chiuten DF; Umsawasdi T; Dhingra HM; Bodey GP; Valdivieso M
Cancer Treat Rep; 1985 Nov; 69(11):1327-8. PubMed ID: 3867406
[No Abstract] [Full Text] [Related]
11. Phase II trial of diaziquone in advanced upper aerodigestive cancer.
Creagan ET; Long HJ; Kvols LK; Edmonson JH; O'Fallon JR
Cancer Treat Rep; 1985 Jan; 69(1):141. PubMed ID: 3967258
[No Abstract] [Full Text] [Related]
12. Phase II trial of diaziquone in advanced ovarian carcinoma. European Organization for Research on Treatment of Cancer Early Clinical Trials Group.
Lund B; Bramwell V; Renard J; Hansen HH; Dombernowsky P
Cancer Treat Rep; 1985 Mar; 69(3):339-40. PubMed ID: 3872170
[No Abstract] [Full Text] [Related]
13. Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group Study.
Shildt R; Stephens RL; Subramanian VP; Baker LH; Fletcher WS; O'Bryan RM; McCracken JD
Cancer Treat Rep; 1985 Jun; 69(6):709-10. PubMed ID: 4016775
[No Abstract] [Full Text] [Related]
14. Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Sutton GP; Homesley HD; Park R
Cancer Treat Rep; 1986 Feb; 70(2):309-10. PubMed ID: 3948196
[No Abstract] [Full Text] [Related]
15. Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study.
Stuckey WJ; Crowley J; Baker LH; Larrimer NR; Hanson KH; Bonnet JD; White LA
Cancer Treat Rep; 1987 Nov; 71(11):1095-6. PubMed ID: 3119202
[No Abstract] [Full Text] [Related]
16. Phase II trial of diaziquone in malignant mesothelioma.
Eagan RT; Frytak S; Richardson RL; Creagan ET; Nichols WC
Cancer Treat Rep; 1986 Mar; 70(3):429. PubMed ID: 3955559
[No Abstract] [Full Text] [Related]
17. Phase II clinical trial of diaziquone in the treatment of patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Stehman FB; Malfetano J
Cancer Treat Rep; 1986 Sep; 70(9):1127-8. PubMed ID: 3742494
[No Abstract] [Full Text] [Related]
18. Phase II trial of diaziquone in advanced renal adenocarcinoma.
Hansen M; Gallmeier WM; Vermorken J; Holdener E; Hansen HH; Renard J; Rozencweig M
Cancer Treat Rep; 1984; 68(7-8):1055-6. PubMed ID: 6744342
[No Abstract] [Full Text] [Related]
19. Phase II evaluation of diaziquone in recurrent head and neck cancer.
Kish JA; Ensley J; Al-Sarraf M
Cancer Treat Rep; 1986 May; 70(5):671-2. PubMed ID: 3708616
[No Abstract] [Full Text] [Related]
20. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6 -dioxodiethylester) in recurring supratentorial malignant brain gliomas--a Phase II study. EORTC Brain Tumour Cooperative Group.
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):143-6. PubMed ID: 4038653
[No Abstract] [Full Text] [Related]
[Next] [New Search]
